SEPP1 Levels in Differnet Glucose Tolerance StatusNCT01258426
Human Selenoprotein P Concentration With Glucose Tolerance Status
An observational study of SEPP1 Levels in Differnet Glucose Tolerance Status, run by Korea University.
Trial summary
Recently, seslenium(Se) has known as important regulator in metabolic status, lipid profile, atherosclerosis progression. SEPP1(selenoprotein P1)is a secreted protein from mainly liver. This protein is used as an index of selenium nutritional status. Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- SEPP1 Levels in Differnet Glucose Tolerance Status
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Total 180 patients Normal 60-IGT 60-T2DM 60
Who may be able to join
- 20-80 years old
- Not severe medical condition
Who cannot join
- metformin, insulin using type 2 diabetes
About this study
Recently, seslenium(Se) has known as important regulator in metabolic status, lipid profile, atherosclerosis progression. SEPP1(selenoprotein P1)is a secreted protein from mainly liver. This protein is used as an index of selenium nutritional status. The association between the concentration of SEPP1(selenoprotein P1) in normal glucose tolerance,impaired glucose tolerance, type 2 diabetes is still a matter of debate. This cross sectional study will evaluate whether glucose status is matter in SEPP1 level.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Normal, IGT, T2DM | Not described |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2010 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SEPP1 Levels in Differnet Glucose Tolerance StatusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
Sponsor and investigators
- Lead sponsor
- Korea University
- Sponsor type
- University, hospital or other
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01258426
- Sponsor's protocol ID
- SEPP1(DM)
- Status last verified
- Dec 2010
- First submitted
- 10 Dec 2010
- Last updated
- 13 Dec 2010
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Dec 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Human Selenoprotein P Concentration With Glucose Tolerance Status
- ClinicalTrials.gov ID
- NCT01258426
- Acronym / sponsor ID
- SEPP1(DM)
- Study type
- Observational
- Recruitment status
- Completed
- Lead sponsor
- Korea UniversityUniversity, hospital or other
- First posted
- 13 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, seslenium(Se) has known as important regulator in metabolic status, lipid profile, atherosclerosis progression. SEPP1(selenoprotein P1)is a secreted protein from mainly liver. This protein is used as an index of selenium nutritional status. The association between the concentration of SEPP1(selenoprotein P1) in normal glucose tolerance,impaired glucose tolerance, type 2 diabetes is still a matter of debate. This cross sectional study will evaluate whether glucose status is matter in SEPP1 level.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Normal, IGT, T2DM | – | – |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Total 180 patients Normal 60-IGT 60-T2DM 60
Key inclusion criteria (2 listed)
- 20-80 years old
- Not severe medical condition
Key exclusion criteria (1 listed)
- metformin, insulin using type 2 diabetes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Dec 2010.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of SEPP1 Levels in Differnet Glucose Tolerance Status, run by Korea University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Dec 2010. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2010.